EUVIMEDEUVIMED entdecken
Open Access

Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19

Wesley H Self, Matthew S Shotwell, Kevin W Gibbs, Marjolein de Wit, D Clark Files, Michelle Harkins, Kristin M Hudock, Lisa H Merck, Ari Moskowitz, Krystle D Apodaca, Aaron Barksdale, Basmah Safdar und 35 weitere

JAMA · 2023

DOI: 10.1001/jama.2023.3546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, 2023. Verfasst von Wesley H Self und 46 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Institute for Clinical and Translational Research, Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tenn…. Hauptthemen laut MEDLINE: COVID-19, Receptor, Angiotensin, Type 1, Renin-Angiotensin System, Vasodilator Agents. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCATS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Preclinical models suggest dysregulation of the renin-angiotensin system (RAS) caused by SARS-CoV-2 infection may increase the relative activity of angiotensin II compared with angiotensin (1-7) and may be an important contributor to COVID-19 pathophysiology.

Objective

To evaluate the efficacy and safety of RAS modulation using 2 investigational RAS agents, TXA-127 (synthetic angiotensin [1-7]) and TRV-027 (an angiotensin II type 1 receptor–biased ligand), that are hypothesized to potentiate the action of angiotensin (1-7) and mitigate the action of the angiotensin II. Design, Setting, and Participants Two randomized clinical trials including adults hospitalized with acute COVID-19 and new-onset hypoxemia were conducted at 35 sites in the US between July 22, 2021, and April 20, 2022; last follow-up visit: July 26, 2022.

Interventions

A 0.5-mg/kg intravenous infusion of TXA-127 once daily for 5 days or placebo. A 12-mg/h continuous intravenous infusion of TRV-027 for 5 days or placebo. Main Outcomes and Measures The primary outcome was oxygen-free days, an ordinal outcome that classifies a patient’s status at day 28 based on mortality and duration of supplemental oxygen use; an adjusted odds ratio (OR) greater than 1.0 indicated superiority of the RAS agent vs placebo. A key secondary outcome was 28-day all-cause mortality. Safety outcomes included allergic reaction, new kidney replacement therapy, and hypotension.

Results

Both trials met prespecified early stopping criteria for a low probability of efficacy. Of 343 patients in the TXA-127 trial (226 [65.9%] aged 31-64 years, 200 [58.3%] men, 225 [65.6%] White, and 274 [79.9%] not Hispanic), 170 received TXA-127 and 173 received placebo. Of 290 patients in the TRV-027 trial (199 [68.6%] aged 31-64 years, 168 [57.9%] men, 195 [67.2%] White, and 225 [77.6%] not Hispanic), 145 received TRV-027 and 145 received placebo. Compared with placebo, both TXA-127 (unadjusted mean difference, −2.3 [95% CrI, −4.8 to 0.2]; adjusted OR, 0.88 [95% CrI, 0.59 to 1.30]) and TRV-027 (unadjusted mean difference, −2.4 [95% CrI, −5.1 to 0.3]; adjusted OR, 0.74 [95% CrI, 0.48 to 1.13]) resulted in no difference in oxygen-free days. In the TXA-127 trial, 28-day all-cause mortality occurred in 22 of 163 patients (13.5%) in the TXA-127 group vs 22 of 166 patients (13.3%) in the placebo group (adjusted OR, 0.83 [95% CrI, 0.41 to 1.66]). In the TRV-027 trial, 28-day all-cause mortality occurred in 29 of 141 patients (20.6%) in the TRV-027 group vs 18 of 140 patients (12.9%) in the placebo group (adjusted OR, 1.52 [95% CrI, 0.75 to 3.08]). The frequency of the safety outcomes was similar with either TXA-127 or TRV-027 vs placebo. Conclusions and Relevance In adults with severe COVID-19, RAS modulation (TXA-127 or TRV-027) did not improve oxygen-free days vs placebo. These results do not support the hypotheses that pharmacological interventions that selectively block the angiotensin II type 1 receptor or increase angiotensin (1-7) improve outcomes for patients with severe COVID-19. Trial Registration ClinicalTrials.gov Identifier: NCT04924660

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Receptor, Angiotensin, Type 1Renin-Angiotensin SystemVasodilator AgentsAdultFemaleHumansMaleMiddle AgedAngiotensin IIAngiotensinsHypoxiaInfusions, IntravenousLigandsOligopeptidesRandomized Controlled Trials as TopicSARS-CoV-2Angiotensin IPeptide Fragments

Substanzen

Angiotensin IIAngiotensinsLigandsOligopeptidesReceptor, Angiotensin, Type 1Vasodilator Agentsangiotensin I (1-7)Angiotensin IPeptide FragmentsSar-Arg-Val-Tyr-Ile-His-Pro-Ala-OH

Autor:innen und Institutionen

  • Vanderbilt Institute for Clinical and Translational Research, Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Department of Medicine, Wake Forest University, Winston-Salem, North Carolina.
  • Department of Medicine, Virginia Commonwealth University, Richmond.
  • Department of Internal Medicine, University of New Mexico, Albuquerque.
  • Department of Medicine, University of Cincinnati, Cincinnati, Ohio.

Förderung

  • NINDS NIH HHS
  • NCATS NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Self, W. H., Shotwell, M. S., Gibbs, K. W., de Wit, M., Files, D. C., Harkins, M., Hudock, K. M., Merck, L. H., Moskowitz, A., Apodaca, K. D., Barksdale, A., Safdar, B., Javaheri, A., Sturek, J. M., Schrager, H., Iovine, N., Tiffany, B., Douglas, I. S., Levitt, J., …, & ACTIV-4 Host Tissue Investigators (2023). Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19. JAMA. https://doi.org/10.1001/jama.2023.3546

Vancouver

Self WH, Shotwell MS, Gibbs KW, de Wit M, Files DC, Harkins M, et al. Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19. JAMA. 2023. doi:10.1001/jama.2023.3546

BibTeX
@article{Self2023,
  author = {Self, Wesley H and Shotwell, Matthew S and Gibbs, Kevin W and de Wit, Marjolein and Files, D Clark and Harkins, Michelle and Hudock, Kristin M and Merck, Lisa H and Moskowitz, Ari and Apodaca, Krystle D and Barksdale, Aaron and Safdar, Basmah and Javaheri, Ali and Sturek, Jeffrey M and Schrager, Harry and Iovine, Nicole and Tiffany, Brian and Douglas, Ivor S and Levitt, Joseph and Busse, Laurence W and Ginde, Adit A and Brown, Samuel M and Hager, David N and Boyle, Katherine and Duggal, Abhijit and Khan, Akram and Lanspa, Michael and Chen, Peter and Puskarich, Michael and Vonderhaar, Derek and Venkateshaiah, Lokesh and Gentile, Nina and Rosenberg, Yves and Troendle, James and Bistran-Hall, Amanda J and DeClercq, Josh and Lavieri, Robert and Joly, Meghan Morrison and Orr, Michael and Pulley, Jill and Rice, Todd W and Schildcrout, Jonathan S and Semler, Matthew W and Wang, Li and Bernard, Gordon R and Collins, Sean P and ACTIV-4 Host Tissue Investigators, ACTIV-4 Host Tissue Investigators},
  title = {Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19},
  journal = {JAMA},
  year = {2023},
  doi = {10.1001/jama.2023.3546}
}
Kostenlos starten →